The Guillain-Barre syndrome (GBS) is an acute monophasic illness causing a rapidly progressive polyneuropathy with weakness or paralysis.1 The main stay of therapy for GBS includes plasmaphoresis or administration of
intravenous immune globulin.2 Both therapies are recommended for those patients who are unable to walk unaided, demonstrate worsening lung vital capacities and require mechanical ventilation who present within four weeks of symptom onset.
Intravenous immune globulin in the therapy of peripartum cardiomyopathy.
As with other
intravenous immune globulin products, the infusion should be started slowly.
Treatment with
intravenous immune globulin (IVIG, 400 mg/kg) was started on day 4 and given for 5 consecutive days, which resulted in marked and continued neurologic improvement.
Meta-analyses of the effectiveness of
intravenous immune globulin for prevention and treatment of neonatal sepsis.
It is a specialty plasma-derived, polyclonal
intravenous immune globulin, and includes naturally occurring polyclonal antibodies and high levels of antibodies targeted to respiratory syncytial virus or RSV.
ATLANTA --
Intravenous immune globulin should be the primary means of postexposure prophylaxis among persons at high risk of severe varicella complications if there is a shortage of varicella zoster immune globulin, according to a vote by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
ATLANTA --
Intravenous immune globulin should be the primary means of post-exposure prophylaxis among persons at high risk of severe varicella complications if there is a shortage of varicella zoster immune globulin, according to a vote by the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices.
Among the factors favoring the use of
intravenous immune globulin (WIG) for postexposure prophylaxis is the fact that it usually is in ample supply, although there have been some shortages in the past, said Philip LaRussa, M.D., of the division of pediatric infectious diseases, Columbia Presbyterian Medical Center, New York City.
The use of
intravenous immune globulin in immunodeficiency diseases.
Under the contract, Biotest Pharmaceuticals will offer manufacturing services and license proprietary fractionation and purification manufacturing process for Respiratory Syncytial Virus
intravenous immune globulin to ADMA Biologics.